The Boston-area device maker teaching a high-energy laser to treat skin the industry left behind - safely, at any depth, on any tone.
For as long as aesthetic lasers have existed, they have come with an asterisk. The most powerful devices - the ones that resurface skin, erase pigment, and smooth scars - carried a warning that made them risky, sometimes off-limits, for patients with darker skin. Melanin absorbs laser energy, and a machine tuned for the easy cases could burn or discolor the skin it was meant to help. The industry largely accepted this as a fact of physics. AVAVA, Inc. treated it as a design problem.
Based in Waltham, Massachusetts, AVAVA is a medical aesthetics company building a new class of energy-based laser platforms for skin renewal. Its flagship, the MIRIA Skin Treatment System, is an FDA-cleared device that pairs patented Focal Point Technology with AI-driven skin visualization. The pitch is specific and unusually inclusive: high-energy skin renewal that works across all six Fitzpatrick skin types, not just the lightest ones.
The company did not emerge from a garage. It was spun out of Blossom Innovations, a Boston-based med-tech incubator, and its core intellectual property traces back to the Wellman Center for Photomedicine at Massachusetts General Hospital - one of the most storied laser-medicine labs in the world. The scientists attached to AVAVA's technology have names that carry weight in dermatology: R. Rox Anderson, Dieter Manstein, and Henry H.L. Chan, researchers whose earlier work underpins famous platforms like Fraxel fractional resurfacing and CoolSculpting. Leading the company as founder, CEO, and President is Irina Erenburg, who also founded Blossom Innovations before carving AVAVA out to commercialize the laser on its own.
Conventional fractional lasers deposit most of their energy at or near the skin's surface. That works, but it forces a tradeoff: turn up the power for deeper, more effective treatment and you raise the risk of surface damage - a risk that grows sharply for patients with more melanin. The result is that some of the most common and stubborn conditions - melasma, hyperpigmentation, and acne scarring - have been the hardest to treat safely in exactly the populations most affected by them.
MIRIA's answer is Focal Point Technology. Instead of scattering energy across the surface, the system focuses laser energy intradermally, placing it at a chosen depth inside the skin with what AVAVA describes as pinpoint accuracy. Because the energy is concentrated where it is needed and spared where it is not, the platform can more than double the current therapeutic energy dose while protecting surrounding tissue. An integrated cooling system, ComfortCool, further shields the skin's surface during treatment.
The payoff is inclusion by engineering. By controlling where energy lands, AVAVA can treat darker skin tones that high-energy lasers historically excluded - and it has the clinical receipts, with a study published in the Journal of the American Academy of Dermatology reporting consistent results, high efficacy, and minimal downtime across diverse patient populations.
A first-in-class, FDA-cleared high-energy laser for skin renewal. Cleared for skin aging, benign pigmented lesions including hyperpigmentation and melasma, and acne scars - validated across all Fitzpatrick skin types.
The patented method of focusing laser energy at a chosen depth inside the skin, enabling higher therapeutic doses with less collateral damage and safety across skin tones.
Integrated skin-cooling that protects surrounding tissue and improves patient comfort during high-energy treatment sessions.
A patient engagement app and a provider workflow platform with AI-driven skin visualization - the intelligence layer wrapped around the hardware for planning and monitoring treatments.
AVAVA sells to dermatologists, plastic surgeons, and medical aesthetic practices, who deliver MIRIA treatments to their patients. The device has appeared in dermatology offices from Fresno to across the U.S., with a clear focus on patients seeking pigment, melasma, and acne-scar treatment - especially those with darker skin tones underserved by legacy lasers.
A B2B2C medical-device model: capital sales of the MIRIA platform to practices, recurring revenue from consumables and service, and software (MyAVAVA, AVAVASyncPro) that deepens the provider-patient relationship. The company builds the ecosystem, not just the box.
In June 2024, AVAVA secured $35 million in financing to support the commercial expansion of MIRIA - not to prove a hypothesis, but to scale a device that already had FDA clearances and clinical validation in hand. The round included a $25 million Series C anchored by strategic partner Jeisys Medical alongside existing and new investors, plus $10 million in growth capital from Catalio Capital Management.
The strategic dimension matters: Jeisys Medical is itself an aesthetics device company, and Catalio is a health-sciences investor - backers that bring commercial reach, not just capital, to a company moving from clearance to clinics.
Where incumbents like Fraxel, Cutera, and Lumenis deposit energy near the surface, MIRIA places it at a chosen intradermal depth.
Safety and efficacy across Fitzpatrick I–VI is the founding requirement, not an afterthought.
Skin visualization software lets providers see before they treat - hardware plus a decision layer.
The competitive set is crowded with established names - Candela's Fraxel, Cutera, Lumenis, Cynosure and Lutronic, Solta Medical. AVAVA's wedge is not a marginally better version of what they sell; it is the case they have historically handled worst. By designing for the hardest patients first, AVAVA positions MIRIA as the platform practices reach for when a patient's skin tone rules other lasers out.
AVAVA is carved out of the Boston-based med-tech incubator to commercialize a new class of intradermal lasers.
MIRIA earns 510(k) clearance for skin aging and, in August, for benign pigmented lesions including hyperpigmentation.
A Series C led with Jeisys Medical plus growth capital from Catalio fuels commercial expansion.
MIRIA wins NewBeauty's Best Innovation and Best Multitasking Laser, and gains FDA clearance for acne scars across all skin types.
Named Best Multitasking Laser and Best Innovation, and featured among the best in-office treatments.
Peer-reviewed evidence in the Journal of the American Academy of Dermatology confirming inclusive, consistent outcomes.
Skin aging, benign pigmented lesions, hyperpigmentation, and acne scars across all Fitzpatrick skin types.
Featured by Dermatology Times, Bustle, ABC30's Small Business Spotlight, and industry press.
Video links point to search and official channels - AVAVA does not publish a single fixed demo URL.